Observing treatment outcomes in DLBCL patients with different genetic subtypes
A Real-World Study of Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Different Genetic Subtypes
This study looks at how different genetic types of diffuse large B-cell lymphoma (DLBCL) respond to treatments to help improve future care for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06026488 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect and evaluate real-world data on treatment regimens, efficacy, safety, and survival outcomes for patients diagnosed with diffuse large B-cell lymphoma (DLBCL) across various genetic subtypes. By analyzing clinical characteristics and prognostic factors, the study seeks to enhance understanding of how different molecular subtypes of DLBCL respond to treatment. Data will be gathered from actual clinical practice cases, including patient demographics, tumor characteristics, treatment history, and adverse reactions. The findings are expected to inform future precision therapies for DLBCL.
Who should consider this trial
Good fit: Ideal candidates include individuals with histologically-confirmed DLBCL who have a genetic subtype identified through next-generation sequencing.
Not a fit: Patients with severe mental illness or those deemed unsuitable for inclusion by the investigator may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for DLBCL patients based on their genetic subtype.
How similar studies have performed: Other studies have shown success in analyzing genetic subtypes of DLBCL, suggesting that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically-confirmed diffuse large B-cell lymphoma (DLBCL) * Genetic subtype belonging to at least one of the seven subtypes by using next generation sequencing: MCD, BN2, N1, ST2, A53, EZB (MYC+, MYC-) and others * Fully comprehension and signature of the informed consent form (ICF) for participation Exclusion Criteria: * Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period * Severe mental illness * Patients deemed unsuitable for inclusion by the investigator
Where this trial is running
Shanghai, Shanghai Municipality
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Weili Zhao
- Email: zwl_trial@163.com
- Phone: +862164370045
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.